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Background: The association of low-density lipoprotein (LDL) particle composition with 
cardiovascular risk has not been explored before. The aim was to evaluate the relationship 
between baseline LDL particle size and composition (proportions of large, medium and small 
LDL particles over their sum expressed as small-LDL %, medium-LDL % and large-LDL %) 
and incident cardiovascular disease in a population-based study. 
Methods: Direct measurement of LDL particles was performed using a two-dimensional 
NMR-technique (Liposcale®). LDL cholesterol was assessed using both standard 
photometrical methods and the Liposcale® technique in a representative sample of 1,162 
adult men and women from Spain.  
Results: The geometric mean of total LDL particle concentration in the study sample was 
827.2 mg/dL (95% CI 814.7, 839.8). During a mean follow-up of 12.4 ± 3.3 years, a total of 
159 events occurred. Medium LDL particles were positively associated with all 
cardiovascular disease, coronary heart disease (CHD) and stroke after adjustment for 
traditional risk factors and treatment. Regarding LDL particle composition, the multivariable 
adjusted hazard ratios for CHD for a 5% increase in medium and small LDL % by a 
corresponding decrease of large LDL % were 1.93 (1.55, 2.39) and 1.41 (1.14, 1.74), 
respectively.  
Conclusions: Medium LDL particles were associated with incident cardiovascular disease. 
LDL particles showed the strongest association with cardiovascular events when the particle 
composition, rather than the total concentration, was investigated. A change in baseline 
composition of LDL particles from large to medium and small LDL particles was associated 




















Photometrically assessed low-density lipoprotein (LDL) cholesterol is a standard measure for 
cardiovascular risk stratification and is directly related to the total amount of cholesterol, 
which is transported by LDL particles (1). The assessment of LDL particles carrying 
cholesterol is feasible nowadays using sophisticated techniques of lipidomics including 
nuclear magnetic resonance (NMR) spectroscopy (2). The size, lipid content and number of 
LDL particles can be measured using NMR-based Advanced Lipoprotein Testing (ALT) and 
subfractionation, and the resulting LDL particle subclasses are commonly divided into large, 
medium and small particles according to their respective size (3). Although the determination 
of lipoprotein by NMR has been performed for some years, both at the level of research and 
commercial tests, most approaches are limited to lipid peaks and analysis of lipoproteins in 
one dimension. The 2D-diffusion ordered spectroscopy (DOSY)-NMR Liposcale®, a two 
dimensional NMR test, is a unique technique able to determine the number of LDL 
lipoprotein particles from direct size measurements, providing more accurate results than the 
commercial alternatives (4). 
 
Over the past years, interest has grown in the predictive value of LDL particle number and 
size, and the determination of LDL particles has been included into the guidelines of the 
American Association of Clinical Endocrinologists for prevention of atherosclerosis (5). 
However, current evidence is mainly based on studies conducted in patients with elevated 
cardiovascular risk or sub-studies of clinical trials addressing the effect of lipid-lowering 
treatment, thus, available data on the relationship between NMR-measured LDL particles 
and cardiovascular events in the general population is scarce (6–10). Moreover, inconsistent 
findings have been reported regarding the relationship of LDL subclasses with 
cardiovascular disease. Small, medium and large LDL particles have been associated with a 















available studies is challenging due to differences in terms of study population, outcome 
variables of interest, particle assessment method and statistical analysis (11–14). 
Furthermore, the potential role of LDL particle subclasses’ composition (proportions of large, 
medium and small LDL particles over their sum expressed as small-LDL %, medium-LDL % 
and large-LDL %), rather than absolute concentrations, on cardiovascular disease has not 
been explored before.  
 
The objective of the present study was to evaluate the association of total LDL cholesterol, 
LDL particle size, concentration and LDL particle composition with incident cardiovascular 
disease in adult men and women participating in the Hortega Follow-up Study, a cohort 




  The Hortega Study is a population-based survey among adults 15-85 years old 
residing in the conscription area of the Rio Hortega University Hospital in Valladolid (central 
Spain). The Hortega Study started in 1997 as a mail survey on a random sample of 20% of 
public health system beneficiaries (Hortega Phase I), followed by a pilot examination of 
randomly selected individuals who responded to the questionnaire (Hortega Phase II). In 
2001-2002 the Hortega study (phase III) examined and interviewed a representative sample 
of 1502 phase I participants (including re-examination of the phase II- pilot study- 
participants). In 2001-2002, urine and blood samples were collected from all Hortega Study 
participants and immediately stored at -80 ºC at the Hospital Rio Hortega, Valladolid (Spain), 
with no sample losses and following standardized protocols and standard quality control 
procedures. Incident health endpoints and mortality during follow-up were assessed in 2015 















records (phase IV). The study sample consisted of 1,502 total participants with stored 
plasma samples for Liposcale® determinations. 144 participants were excluded due to 
prevalent CVD, 10 participants due to missing Liposcale® measures and 186 participants 
due to missing data in other relevant covariates, leaving 1,162 participants for the present 
study. The research protocol was approved by the Ethics Committee of the Rio Hortega 
University Hospital and all participants provided written informed consent.  
 
Lipid profiling 
For the measurement of “standard” lipid levels, plasma total cholesterol, high-density 
lipoprotein (HDL)-cholesterol, and total triglycerides (TG) concentrations in non-fasting 
samples were determined using a Hitachi 917 analyzer. LDL cholesterol was calculated 
using the Friedewald formula. 
 Elevated total cholesterol, LDL cholesterol and TG were defined as > 200 mg/dl, > 
130 mg/dl, and > 150 mg/dl, respectively. Low HDL cholesterol was defined as < 40 mg/dl in 
men or < 50 mg/dl in women.  
  In 2015, 500 μl of blood plasma samples were shipped on dry ice to the Biosfer 
Teslab facilities (Reus, Spain) for Liposcale® lipoprotein analysis by Nuclear Magnetic 
Resonance (NMR), contracting a reliable shipping service to maintain the cold chain and 
guarantee that they arrive frozen. Before the NMR analysis, the samples were completely 
thawed, homogenized and transferred to the NMR tubes in a controlled temperature of 4ºC. 
The size, lipid content and the number of the LDL particles were determined as previously 
reported (4). Briefly, particle concentration and the diffusion coefficients were obtained from 
the measured amplitudes and attenuation of their spectroscopically distinct lipid methyl 
group NMR signals, using the 2D diffusion-ordered 1H NMR spectroscopy (DSTE) pulse. 
LDL subtypes were identified according to their diffusion coefficients. The area of each 
lorentzian function was related to the lipid concentration of each lipoprotein subtype, and the 















each lipoprotein subtype (p) were calculated by dividing the lipid volume by the particle 
volume of a given class. The lipid volumes were determined by using common conversion 
factors to convert concentration units into volume units. The lower and upper detection limits 
for total LDL-p, large LDL-p, medium LDL-p and small LDL-p were, respectively, 100-3000 
nmol/L, 0.5-500 nmol/L, 0.5-1000 nmol/L, and 100-2000 nmol/L. No sample had levels below 
or above these limits. The inter-assay coefficient of variation for total LDL-p, large LDL-p, 
medium LDL-p, and small LDL-p were 3, 4, 5, and 5 %, respectively. 
 
Cardiovascular endpoints definitions 
The primary outcome of this study was all cardiovascular disease incidence, including 
both fatal and non-fatal events, which was defined as mortality or the first episode of 
hospitalization by any cardiovascular cause (International Classification of Diseases, 10th 
Revision (ICD-10) codes I00-I78). Secondarily, findings for incident coronary heart disease 
(CHD) and stroke were reported. Detailed definitions of fatal and nonfatal events follow the 
guidelines published by the 2014 American College of Cardiology and American Heart 
Association Task Force on Clinical Data Standards Committee (15). Incident CHD was 
defined as the first occurrence of definite fatal myocardial infarction, sudden death due to 
CHD, nonfatal myocardial infarction, or definite non-fatal CHD. Incident cases of stroke were 
defined as the first occurrence of definite or possible fatal or definite non-fatal stroke. Time to 
event was calculated as the difference between the date of the baseline examination and the 
date of the cardiovascular event, the date of death, or 30 November 2015 (administrative 
censoring), whichever occurred first.  
 
Other Variables 
Information on age, sex, education, smoking status, and lipid-lowering medication was 
based on self-report. Blood samples were obtained after an average of 3 h since the last 















auto-analyzer (Hitachi 704, Boehringer Mannheim, Germany), and a second fasting glucose 
determination was obtained only in subjects with non-fasting glucose levels equal to or 
higher than 140 mg/dl. Glycosylated hemoglobin (HbA1c) levels were measured from 
capillary blood samples with a DCA 2000 HbA1c analyzer (Bayer Diagnostics, Tarrytown, 
NY). Type 2 diabetes (T2D) was defined as a fasting glucose levels of 126 mg/dL or greater, 
HbA1c > 6.5%, by physician diagnosis or as a use of glucose-lowering medications in the 
health records. Blood pressure was measured up to three times in sitting position and 
‘hypertension’ was defined as a mean SBP/DBP of at least 140/90 mmHg, a recorded 
physician diagnosis, or medication use. Urine albumin was measured by automated 
nephelometric immunochemistry (Behring Institute). Chronic kidney disease was defined 
according to the Kidney disease improving global outcomes (KDIGO) criteria as an 
estimated glomerular filtration rate lower than 60 ml/min/1.73m2 (16) or as albuminuria levels 
greater than 20 mg/g creatinine in men and 30 mg/g creatinine in women. 
 
Statistical Methods 
The survey package in R software (version 3.0.3; R Development Core Team 2014) 
was used to account for the sampling design and survey weights. Baseline data are 
presented as means and standard deviation for continuous variables and N (%) for 
categorical variables. LDL particles were not normally distributed and have been, thus, log-
transformed for all statistical analyses. Subgroup analyses were performed to evaluate the 
characteristics of individuals with predominantly large, medium or small LDL particles. 
Spearman’s correlation among lipid biomarkers was calculated. The prospective association 
of lipid biomarkers with mortality and cardiovascular incidence endpoints was evaluated 
using Cox-proportional hazard models. Lipid biomarkers were introduced in the models 
using previously defined categories for altered lipid levels and as continuous concentrations 















The potential role of lipoprotein particle composition on mortality and cardiovascular 
incidence endpoints was evaluated examining the relationship between a 5% increase in the 
relative amount of lipoprotein particle subtypes over the sum of lipoproteins (expressed as 
small LDL-p %, medium LDL-p % and large LDL-p %) and the study endpoints. In the 
conventional approach, each lipoprotein particles biomarker proportion alone was entered 
into the regression model, however, findings from the conventional approach are challenging 
to interpret.  For instance, the increase in small LDL-p% could be related to a decrease in 
either medium LDL-p% or large LDL-p%, as the sum of small LDL-p%, medium LDL-p and 
large LDL-p equal 1. To address this issue, a “leave-one-out” approach was used (17,18). In 
this method, two LDL-p particles concentration variables are entered at a time. For example, 
small LDL-p% and medium LDL-p % are entered together leaving out large LDL-p %. The 
regression coefficients thus estimate the hazard ratio associated with an increase in small 
LDL-p % by a corresponding decrease in large LDL-p%, and with an increase in medium 
LDL-p% by a corresponding decrease in large LDL-p%, respectively.  
 
Results  
Study population and lipid profile 
A total of 1,162 subjects (49% male, mean age 49.7 years) was included into the 
study. Main demographic characteristics are shown in table 1. In terms of cardiovascular risk 
factors, the characteristics of the study population followed a distribution as expected in the 
Spanish general population. Subjects with incident stroke – as compared to subjects with 
incident CHD - were older, had a higher rate of obesity and dyslipidemia but a lower rate of 
former or current smoking status, diabetes and hypertension. 
Distributions of standard lipids and NMR lipoproteins are shown in table 1. The geometric 















geometric mean levels of standard lipid equivalents, whereas a higher mean HDL 
cholesterol concentration and a lower mean triglyceride concentration was found when lipids 
were assessed with NMR. The correlation between standard and NMR-measured lipids 
showed Spearman´s correlation coefficients of around 0.90 (supplemental figure 1). 
The distribution of LDL cholesterol particle (LDL-p) composition was as follows: small LDL-p 
was predominant (median proportion 49.6%, (interquartilic range 47.4% - 52.5%)), followed 
by medium LDL-p (median proportion 35%, (interquartilic range 32.5% - 36.8%) and large 
LDL-p (median proportion 15.7%, (interquartilic range 14.5% - 16.9%)). Individuals below 
median levels of large LDL-p % showed a less favourable cardiovascular risk profile 
compared to subjects above median levels of large LDL-p % (supplemental Table 1). 
Association of lipoproteins with CVD 
During a mean-follow up of 12.4 ± 3.3 years, the total number of events was 159 for 
all CVD, 42 for CHD and 60 for stroke. The Hazard Ratios of lipid parameters for all CVD, 
CHD and stroke are shown in supplemental figure 2. In fully adjusted models (see 
description in supplemental figure 2), LDL concentrations and the total cholesterol/HDL 
ratios were positively associated with the risk for all events, whereas the association with 
HDL concentrations was inverse. Observed risk ratios were similar for both standard and 
NMR-measured lipids except for the association of total cholesterol and CHD, which showed 
a statistically significant association only when the lipid was measured with the standard 
method. Overall, the magnitude of the association of lipid concentration and events was 
attenuated but remained significant in NMR-measured lipids compared to standard lipids. 
Association of LDL particles with CVD 
The Hazard Ratios for LDL particle concentration and size are shown in table 2. Total 















factors were controlled for. Medium LDL-p, but not small LDL-p, were positively and linearly 
associated with the risk of all CVD, CHD and stroke in fully adjusted statistical models.  
The relevance of LDL particles was further evaluated in a compositional analysis using a 
leave-one-out approach (table 3). The strongest associations were observed for LDL-p and 
CHD when the proportion of medium and small LDL-p were entered simultaneously into the 
model. A 5% increase in the proportion of medium LDL-p by a corresponding decrease in 
the proportion of large LDL-p was associated with an increase in risk for all events (HRs 1.19 
(1.07, 1.32), 1.93 (1.55, 2.39) and 1.20 (1.00, 1.44) for all-CVD, CHD and stroke, 
respectively). A 5% increase in the proportion of small LDL-p by a corresponding decrease 
in the proportion of large LDL-p was associated with an increase in risk for CHD (HR 1.41 
(1.14, 1.74)) (table 3). In other words, a change in baseline LDL composition from large to 
medium and small was associated with a 2-fold and 40% increase in risk for CHD, 
respectively (figure 1). In addition, a 5% increase in the proportion of medium LDL-p by a 
corresponding decrease in the proportion of small LDL-p was associated with a statistically 




In a representative sample of a general population from Spain, NMR-measured LDL particle 
concentration and composition were associated with cardiovascular disease incidence. For 
total lipoprotein concentrations, the magnitude of the observed associations was similar 
comparing the standard and NMR measurements, after adjustment for cardiovascular and 
lipid risk factors. Among the LDL particle subclasses, medium LDL particles showed the 
strongest association with cardiovascular events, particularly for CHD. The observed risk 















composition rather than the absolute particle number was assessed. Specifically, a decrease 
in large LDL particles by a corresponding increase in medium or small LDL particles was 
associated with a 2-fold and 40% increase in risk for CHD, respectively.  
 
The present study was performed in a representative sample of the general population. Study 
participants were recruited from the catchment area of the Rio Hortega University Hospital in 
Valladolid, Spain, a hospital with a low rate of external patient admission. The levels of 
measured LDL-cholesterol in this population was in agreement with other population-based 
studies (19). Cross-sectional studies conducted in the US, including data from the 
Cardiovascular Health Study, the Women’s Health Study and the Framingham Offspring Study, 
support the predictive role of LDL particle number for cardiac events, especially in women 
(11,20–22). In Europe, the Finnish FINRISK study included more than 7000 individuals without 
cardiovascular disease at baseline and showed that NMR-measured LDL particle concentration 
was associated with cardiovascular events (12). A nested case-control study in the EPIC-
Norfolk, conducted in more than 2800 individuals from United Kingdom, related LDL particle 
concentration to CHD in healthy subjects (23). The Hazard Ratios for cardiovascular events in 
these studies were generally higher than the risk ratio of total LDL particle concentration 
observed in the present study, and it has been hypothesized that the predictive power of LDL 
particles might be superior to risk management based on standard cholesterol values (24). 
Nonetheless, the adjustments in statistical models vary considerably from one study to another. 
The increased risk attributed to particles is largely attenuated when lipids and variables related 
with metabolic syndrome, including obesity, hyperglycemia, hypertriglyceridemia, low HDL 
cholesterol and hypertension are entered into the regression models (25,26).  
Furthermore, discrepancies regarding the relationship between LDL particle subclasses and 
cardiovascular risk have been. In fully adjusted models, large LDL particles have been related 
with higher (6,12,13), lower (9,11) and null (7,14,21,27) risk for cardiovascular disease. 















reported to be positive (11–13) although in some cases non- statistically significant (9,27). Small 
LDL particles are generally considered to be strongly related to cardiovascular disease due to 
augmented oxidation and delivery of cholesterol to atheromatous plaques, but the statistical 
significance is frequently lost after adjustment for lipoproteins (24). Moreover, LDL particles 
were not associated with future cardiovascular events in patients with metabolic syndrome, a 
condition characterized by an increase in small, dense LDL particles with typically normal LDL 
cholesterol values (14,28). It has been postulated that an elevated small LDL particle 
concentration – at normal total LDL cholesterol levels - might be representative of the so-called 
residual cardiovascular risk. Nevertheless, the exact role of LDL particles and their subclasses 
on cardiovascular risk is not fully understood (29).  
In the present study, conducted in a representative sample of a general South European 
population, medium LDL particles showed the highest association with cardiovascular events in 
conventional Cox-models, even after adjustment for total LDL particle subclass concentration. 
Small LDL particles as a continuous variable were positively related to stroke in models 
adjusting for CV risk factor but surprisingly showed an inverse association with all-CVD and 
CHD. Gender (30), age (31), ethnicity (32–34) and body fat composition (35,36) are main 
determinants of lipoprotein subclasses distribution in the population. Currently available studies 
were mainly conducted in high risk patients or healthy subjects, including predominantly women. 
Therefore, differences regarding the concentration and predictive value of particles can be 
expected when a general population is investigated. The discrepancies regarding the predictive 
value of individual LDL particle subclasses across studies could be also partly due to 
methodological issues. For instance, comparison between the different studies performed on 
lipoprotein profiles is limited by the lack of standardization between the different analytical 
methods used for the determination of lipoprotein profiles.  
Lipoprotein particles can be ascertained using NMR, gradient gel electrophoresis, 
vertical auto profile ultracentrifugation or ion mobility (2). In this study, we used the Liposcale® 















NMR spectroscopy (DOSY), which directly measures the size of lipoprotein particles. This 
methodology has been previously validated and compared to the established one-dimensional 
(1D) NMR method developed by Jeyarajah et al. (37). The LDL particle measurements obtained 
by using 1D and 2D-NMR techniques were highly correlated, although the LDL particle number 
obtained by 2D-NMR method (the Liposcale® test) were more in agreement with biochemical 
values than those obtained using the 1D-NMR test (4). A direct determination of the size and 
number of particles cannot be performed using 1D NMR techniques, since the molecular 
profiles base their results on empirical models, developed by correlations between the crude 
NMR spectrum and biochemical measurements (2). Alternatively, the approximation using 2D 
NMR experiments, whose signal is modulated by the diffusion of the particles in the mixture 
(2D-DOSY-NMR), allows the hydrodynamic characteristics of the molecules, such as the size, 
to be incorporated in the results (38). 
In addition, the NMR-measured LDL particle distribution of any given subject is determined 
by the relative content of cholesterol ester and triglycerides and can vary up to 2-fold across 
individuals (39). In contrast, photometrically assessed standard LDL cholesterol reflects the 
total amount of cholesterol which is transported by LDL particles (1). Total LDL particles 
concentration and standard LDL cholesterol concentrations are highly correlated, but an 
increase or decrease in one LDL particle subtype does not necessarily follow a parallel 
change in the LDL concentrations. For instance, cross-sectional studies have shown that 
individuals with high LDL particle number and low LDL cholesterol concentrations (reflecting 
that the size of the particles is small) or vice versa have a higher risk for cardiovascular 
disease compared to subjects with “concordant” lipoprotein values (26–28, 40–42). The risk 
for cardiovascular disease in patients with an altered relationship of LDL lipoproteins was 
more than 2-fold higher than the risk observed for LDL particle concentration at baseline, 
indicating that an altered composition among LDL lipoproteins rather than the total 
concentration at baseline confers an increase in cardiovascular risk. In our data, the 















with cardiovascular risk, especially for CHD, when the baseline composition, rather than 
individual LDL particles subclasses, is jointly investigated. The strongest association for 
CHD was observed for an increase in the relative amount of medium LDL particles with a 
corresponding decrease in the relative amount of large LDL particles (2-fold risk increase), 
followed by an increase in the relative amount of small LDL particles with a corresponding 
decrease of the relative amount of large LDL particles (41% risk increase), independent of 
total LDL and HDL particle concentration.  
While chance cannot be discarded as a potential explanation for these findings, it is 
well known that the concentrations of LDL particle subclasses are prone to short- and long 
term changes. For example, aerobic exercise is followed by a shift from smaller to larger 
LDL particles, whereas the levels of total cholesterol and LDL cholesterol remain unchanged 
(43,44). Likewise, weight change is associated with a corresponding change in LDL particles 
independent of baseline lipoprotein values (45,46). The beneficial metabolic consequences 
of exercise and weight reduction may therefore be partially explained by a reduction in 
medium and small LDL particles, or an increase in large LDL particles. In the present study, 
individuals above median levels of large LDL particles percent showed a more favourable 
cardiometabolic profile compared to subjects below median levels of large LDL particles 
percent. While findings from our compositional analysis of baseline particles data with 
respect to cardiovascular incidence events collected after more than 12 years of follow-up 
suggest that differences in the baseline LDL particles composition are associated to 
cardiovascular risk, longitudinal studies with repeated measures of LDL particle 
concentrations are desirable in order to obtain an additional insight into the relationship of 
LDL particle subclasses changes over time with cardiovascular outcomes. 
The present study needs to be viewed within its strengths and limitations. For instance, one 
important limitation is the unavailability of all lipid variables that are known to be related to 















treatment was controlled for in regression models, statin type, dosage, and changes in statin 
use during follow-up with its possible effects on cardiovascular events were not available. On 
the other hand, the availability of incident cardiovascular endpoints after more than 12 years 
of follow-up, and the lipoprotein particles determination using state-of-the-art two-
dimensional NMR methods, are major strengths of our study. Other strengths of this study 
include the representative sampling design, which allows the findings to be extrapolated to a 
general population framework. 
 
In conclusion, NMR-measured LDL particles and photometrically assessed LDL cholesterol 
were prospectively associated with cardiovascular risk in a representative sample of a 
general population from Spain. LDL particle subclasses showed a stronger association with 
cardiovascular events when the baseline composition of particle subtypes, rather than the 
absolute concentration of individual subtypes, was investigated. Particularly, the strongest 
positive association with CHD was observed for a decrease in large LDL particles, with a 
corresponding increase in medium or small LDL particles. While the reported associations 
provide some insight into the relation of LDL particles and cardiovascular disease, further 
mechanistic research addressing LDL particle composition changes is needed to understand 
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Table 1. Participant characteristics and overall description of lipoproteins by cardiovascular incidence status. 
    Overall (N=1162) Incident CVD (N=159) 
No incident CVD 
(N=1003) 
Age, years 49.7 ± 18.6 56.9 ± 12 49.4 ± 17.7* 
Male, % 49 60.5 49 
Obesity, % 16.5 25.5 15.9° 
BMI, kg/m2 26.1 ± 4.2 27.4 ± 4.4 26.1 ± 4.1° 
Former smoking, % 27.2 20.2 27.3 
Current smoking, % 27.7 33.3 27.4 
Diabetes, % 5.9 16.2 4.7* 
Glucose lowering medication, 
% 
2.8 9.5 2.1* 
Hypertension, % 35.7 65.3 33.9* 
Antihypertensive medication, 
% 
13 22.8 11.7* 
Systolic blood pressure, 
mmHg  
127.6 ± 21.1 139 ± 22.2 126.9 ± 19.7* 
Diastolic blood pressure, 
mmHg 
79.1 ± 10.6 82.2 ± 11.5 79 ± 10.4* 
Chronic kidney disease, % 8.2 12.5 7.6* 
Dyslipidemia, % 51 69.7 50.6° 
Lipid lowering medication, % 4.8 13.5 4.4° 




Total cholesterol, mg/dL 201.4 ± 37.4 211.2 ± 37.5 201.5 ± 37.3° 
 
LDL-cholesterol, mg/dL 114.5 ± 33.6 127.2 ± 34.3 114.4 ± 33.4° 
 
HDL-cholesterol, mg/dL 52.4 ± 14.2 49 ± 12.9 52.5 ± 14.4✝ 
NMR lipid biomarkers  
  
 
Total cholesterol, mg/dL 202.4 ± 39.6 213 ± 14.8 202.6 ± 39.3° 
 
LDL-cholesterol, mg/dL 116.3 ± 32.3 127.8 ± 33.3 116.3 ± 32° 
 
HDL-cholesterol, mg/dL 61 ± 17.9 57.7 ± 16.3 61.2 ± 18.1✝ 
 
Particle concentration 
(p)   
  
 
Total LDL-p, nmol/L§ 827.2 (814.7, 839.8) 915.8 (859.8, 975.3) 827.8 (814.9, 841)° 
 
Large LDL-p, nmol/L§ 128.5 (126.4, 130.7) 138.3 (129.7, 147.4) 128.6 (126.4, 130.9)
✝ 
 
Medium LDL-p, nmol/L§ 275.2 (269.3, 281.3) 314.3 (293.1, 337.1) 275.1 (268.7, 281.7)° 
 
Small LDL-p, nmol/L§ 415.2 (408.5, 422) 455.8 (426.6, 486.9) 415.7 (408.7, 422.8)° 
  
Data are arithmetic mean ± SD. 
§ Data are geometric mean (95% CI) 
















Table 2. Hazard ratios for cardiovascular incidence endpoints by NMR-measured particles concentrations comparing the 75th versus 25th 
percentile of particles distributions (N=1,162). 
 
   
All-CVD incidence (N events=159) CHD incidence (N events=42) Stroke incidence (N events=60) 
   
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 





   
 
LDL-p  0.99 (0.94, 1.05)  1.10 (1.04, 1.16) --  1.02 (0.92, 1.13)  1.11 (1.01, 1.23) --  1.20 (1.09, 1.31)  1.28 (1.17, 1.41) -- 
  
Large LDL-p  0.96 (0.91, 1.01)  1.06 (1.00, 1.11)  0.94 (0.88, 1.01)  0.88 (0.80, 0.97)  0.96 (0.88, 1.06)  0.69 (0.60, 0.79)  1.06 (0.97, 1.16)  1.13 (1.03, 1.24)  0.92 (0.80, 1.04) 
  
Medium LDL-p  1.03 (0.98, 1.09)  1.15 (1.09, 1.21)  1.07 (0.98, 1.17)  1.20 (1.09, 1.31)  1.38 (1.25, 1.51)  1.34 (1.14, 1.58)  1.28 (1.18, 1.39)  1.38 (1.27, 1.51)  1.50 (1.29, 1.76) 
  
Small LDL-p  0.98 (0.92, 1.03)  1.03 (0.98, 1.09)  0.92 (0.86, 0.98)  0.95 (0.86, 1.04)  0.98 (0.89, 1.07)  0.76 (0.67, 0.86)  1.11 (1.01, 1.22)  1.15 (1.05, 1.26)  0.98 (0.87, 1.11) 
 
 
Model 1 is adjusted for age and sex. 
Model 2 is Model 1 further adjusted for smoking status, obesity, diabetes, hypertension, CKD, anti-hypertensive medication, glucose lowering 
medication, lipid-lowering medication.  

















Table 3. Compositional analysis (leave one-out approach) for NMR-measured LDL cholesterol particles per 
5% increase. 
    % LDL-P Small % LDL-P Medium % LDL-P Large 
    HR (95%CI) HR (95%CI) HR (95%CI) 
     
  
All-CVD incidence 
Standard approach 0.89 (0.85, 0.93) 1.14 (1.09, 1.19) 0.87 (0.79, 0.95) 
Leave-one-out approach    
 
% LDL-P Small - 1.13 (1.09, 1.18) 0.95 (0.86, 1.06) 
 
% LDL-P Medium 0.88 (0.85, 0.92) - 0.84 (0.76, 0.93) 
 
% LDL-P Large 1.05 (0.94, 1.17) 1.19 (1.07, 1.32) - 
     
  
CHD incidence 
Standard approach 0.76 (0.71, 0.83) 1.40 (1.29, 1.53) 0.61 (0.50, 0.73) 
Leave-one-out approach    
 
% LDL-P Small - 1.37 (1.25, 1.49) 0.71 (0.57, 0.88) 
 
% LDL-P Medium 0.73 (0.67, 0.8) - 0.52 (0.42, 0.65) 
 
% LDL-P Large 1.41 (1.14, 1.74) 1.93 (1.55, 2.39) - 
     
  
Stroke incidence 
Standard approach 0.85 (0.79, 0.91) 1.19 (1.11, 1.28) 0.88 (0.74, 1.04) 
Leave-one-out approach    
 
% LDL-P Small - 1.19 (1.10, 1.28) 0.99 (0.82, 1.19) 
 
% LDL-P Medium 0.84 (0.78, 0.91) - 0.83 (0.69, 1.00) 
 
% LDL-P Large 1.01 (0.84, 1.21) 1.20 (1.00, 1.44) - 
 
 
All models are adjusted for age, sex, smoking status, obesity, diabetes, hypertension, CKD, anti-hypertensive 
medication, glucose lowering medication, lipid-lowering medication, total LDL concentration (NMR) and total 
HDL concentration (NMR). 
% LDL-P Small, Small LDL particles proportion 
% LDL-P Medium, Medium LDL particles proportion 















Figure 1. Risk of incident CHD for a decrease in large LDL particles by a corresponding 
increase in medium or small LDL particles. Kaplan-Meier plots for CHD and all-cause CVD 




Group 1: Large LDL particles proportion > Median of Large LDL particles proportion. 
Group 2: Large LDL particles proportion ≤ Median of Large LDL particles proportion and 
Medium LDL particles proportion > Median of Medium LDL particles proportion. 
Group 3: Large LDL particles proportion ≤ Median of Large LDL particles proportion and 























Group 1 580 569 555 540 520 500 481 347
Group 2 307 294 279 265 249 239 232 169




















Group 1 580 576 566 549 521 520 506 505
Group 2 307 298 280 273 261 250 179 179



















 Absolute medium LDL particle concentrations were associated with all cardiovascular 
disease, coronary heart disease and stroke incidence in a representative sample of a 
general population from Spain 
 A change in baseline composition of LDL particles from large to medium and small LDL 
particles was associated with and increased cardiovascular risk, especially for CHD.  
 Subjects with a relative amount of large LDL particles below the median were 
characterized by a less favourable cardiometabolic risk profile compared to individuals 
with a relative amount of large LDL particles above the median. 
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